EDGEWISE THERAPEUTICS INC (EWTX) Fundamental Analysis & Valuation

NASDAQ:EWTX • US28036F1057

Current stock price

31.94 USD
+1.3 (+4.24%)
At close:
31.94 USD
0 (0%)
After Hours:

This EWTX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. EWTX Profitability Analysis

1.1 Basic Checks

  • In the past year EWTX has reported negative net income.
  • EWTX had a negative operating cash flow in the past year.
  • EWTX had negative earnings in each of the past 5 years.
  • In the past 5 years EWTX always reported negative operating cash flow.
EWTX Yearly Net Income VS EBIT VS OCF VS FCFEWTX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 2025 -50M -100M -150M

1.2 Ratios

  • The Return On Assets of EWTX (-30.36%) is comparable to the rest of the industry.
  • Looking at the Return On Equity, with a value of -32.13%, EWTX is in the better half of the industry, outperforming 63.21% of the companies in the same industry.
Industry RankSector Rank
ROA -30.36%
ROE -32.13%
ROIC N/A
ROA(3y)-29.1%
ROA(5y)-24.15%
ROE(3y)-30.89%
ROE(5y)-25.56%
ROIC(3y)N/A
ROIC(5y)N/A
EWTX Yearly ROA, ROE, ROICEWTX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 2025 -10 -20 -30 -40

1.3 Margins

  • EWTX does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
EWTX Yearly Profit, Operating, Gross MarginsEWTX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 2025

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

8

2. EWTX Health Analysis

2.1 Basic Checks

  • Compared to 1 year ago, EWTX has more shares outstanding
  • EWTX has more shares outstanding than it did 5 years ago.
  • EWTX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
EWTX Yearly Shares OutstandingEWTX Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M 100M
EWTX Yearly Total Debt VS Total AssetsEWTX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

2.2 Solvency

  • EWTX has an Altman-Z score of 63.58. This indicates that EWTX is financially healthy and has little risk of bankruptcy at the moment.
  • EWTX's Altman-Z score of 63.58 is amongst the best of the industry. EWTX outperforms 97.41% of its industry peers.
  • There is no outstanding debt for EWTX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 63.58
ROIC/WACCN/A
WACCN/A
EWTX Yearly LT Debt VS Equity VS FCFEWTX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 2025 0 200M 400M

2.3 Liquidity

  • A Current Ratio of 19.85 indicates that EWTX has no problem at all paying its short term obligations.
  • Looking at the Current ratio, with a value of 19.85, EWTX belongs to the top of the industry, outperforming 91.71% of the companies in the same industry.
  • EWTX has a Quick Ratio of 19.85. This indicates that EWTX is financially healthy and has no problem in meeting its short term obligations.
  • EWTX has a better Quick ratio (19.85) than 91.71% of its industry peers.
Industry RankSector Rank
Current Ratio 19.85
Quick Ratio 19.85
EWTX Yearly Current Assets VS Current LiabilitesEWTX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M 500M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

1

3. EWTX Growth Analysis

3.1 Past

  • EWTX shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -12.41%.
EPS 1Y (TTM)-12.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.9%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • EWTX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 19.43% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y-31.92%
EPS Next 2Y-21.7%
EPS Next 3Y-4.21%
EPS Next 5Y19.43%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EWTX Yearly Revenue VS EstimatesEWTX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2027 2028 2029 2030 2031 2032 2033 500M 1B 1.5B 2B 2.5B
EWTX Yearly EPS VS EstimatesEWTX Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2033 0 2 -2 4 6 8

More info and screens

Find the best growth stocksShow best growing peers

0

4. EWTX Valuation Analysis

4.1 Price/Earnings Ratio

  • EWTX reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for EWTX. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
EWTX Price Earnings VS Forward Price EarningsEWTX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
EWTX Per share dataEWTX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

  • EWTX's earnings are expected to decrease with -4.21% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-21.7%
EPS Next 3Y-4.21%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. EWTX Dividend Analysis

5.1 Amount

  • EWTX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

EWTX Fundamentals: All Metrics, Ratios and Statistics

EDGEWISE THERAPEUTICS INC

NASDAQ:EWTX (3/25/2026, 5:20:02 PM)

After market: 31.94 0 (0%)

31.94

+1.3 (+4.24%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)05-06
Inst Owners96.98%
Inst Owner Change12.24%
Ins Owners0.46%
Ins Owner Change0.17%
Market Cap3.43B
Revenue(TTM)N/A
Net Income(TTM)-167.79M
Analysts83.33
Price Target38.93 (21.88%)
Short Float %10.94%
Short Ratio9.44
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-0.96%
Min EPS beat(2)-5.73%
Max EPS beat(2)3.81%
EPS beat(4)3
Avg EPS beat(4)4.9%
Min EPS beat(4)-5.73%
Max EPS beat(4)19.77%
EPS beat(8)7
Avg EPS beat(8)5.8%
EPS beat(12)9
Avg EPS beat(12)4.74%
EPS beat(16)12
Avg EPS beat(16)4.39%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)-8.28%
EPS NQ rev (3m)-8.28%
EPS NY rev (1m)-6.1%
EPS NY rev (3m)-6.1%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 6.56
P/tB 6.56
EV/EBITDA N/A
EPS(TTM)-1.63
EYN/A
EPS(NY)-2.15
Fwd EYN/A
FCF(TTM)-1.34
FCFYN/A
OCF(TTM)-1.34
OCFYN/A
SpS0
BVpS4.87
TBVpS4.87
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -30.36%
ROE -32.13%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-29.1%
ROA(5y)-24.15%
ROE(3y)-30.89%
ROE(5y)-25.56%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 12.28%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 19.85
Quick Ratio 19.85
Altman-Z 63.58
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)148.7%
Cap/Depr(5y)438.85%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-12.41%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-11.9%
EPS Next Y-31.92%
EPS Next 2Y-21.7%
EPS Next 3Y-4.21%
EPS Next 5Y19.43%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-20.51%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-15.4%
EBIT Next 3Y-3.78%
EBIT Next 5Y36.61%
FCF growth 1Y-30.57%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-31.91%
OCF growth 3YN/A
OCF growth 5YN/A

EDGEWISE THERAPEUTICS INC / EWTX Fundamental Analysis FAQ

What is the fundamental rating for EWTX stock?

ChartMill assigns a fundamental rating of 3 / 10 to EWTX.


What is the valuation status of EDGEWISE THERAPEUTICS INC (EWTX) stock?

ChartMill assigns a valuation rating of 0 / 10 to EDGEWISE THERAPEUTICS INC (EWTX). This can be considered as Overvalued.


Can you provide the profitability details for EDGEWISE THERAPEUTICS INC?

EDGEWISE THERAPEUTICS INC (EWTX) has a profitability rating of 1 / 10.